Antibody patents: Danger ahead for biologics
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.
How to protect therapeutic methods in Brazil
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
Agri-patents: The battle of the seeds
An upcoming case on the patent eligibility of genetically modified seed in India will have far-reaching ramifications, as Archana Shankar and Gitika Suri of Anand & Anand explain.
Algorithms—no; computer-implemented methods—yes
It is challenging but not impossible to protect software innovations in Mexico, according to Alejandro Moreno Hernández of Uhthoff, Gomez Vega & Uhthoff.
Conference preview: Reader offer to major US life sciences patents event
ACI’s 17th Global Summit on Life Sciences Patents returns to New York on May 15-17, 2019, to provide practical insights on how to maximise your patent term and develop strategies to enhance protections for your patent portfolio.
Conference preview: ChinaBio Partnering Forum 2019
The 11th annual ChinaBio Partnering Forum global life science partnering event, which will be held on May 8 and 9 in Shanghai, China, is expected to attract more than 1,400 executives from 500-plus life sciences companies spanning an estimated 25 countries.
Conference preview: BIO-Europe Spring convenes in Vienna
The 13th annual BIO-Europe Spring 2019 global life science partnering event will be held March 25–27 in Vienna, Austria. Guadalupe Rodriguez and Kit Muller of EBD Group report.
The future of precision medicine part 4: diagnosing the diagnostic problem
The development of precision treatments must be complemented by the development of precision diagnostics, as Daniel Lim of Kirkland & Ellis explains.
Conference preview: 11th Pharma & Biotech Patent Litigation
SPCs and trade secrets are just two issues set to be discussed at C5’s 11th Pharma & Biotech Patent Litigation, on February 26 and 27 in Amsterdam. LSIPR reports.
Politics and IP: an unhealthy mix
The political influence on patent rights during Brazil’s general election in October has set a worrying precedent, writes Gabriel Di Blasi of Di Blasi Parente & Associados.
